Ebola Virus Disease: Virology, Pathogenesis, Therapy, and Vaccines

Yi SHI,Ying CHENG,Jun LIU,Xiang N,HongJie YU,Yu LI,Zhai LIU,George F GAO

DOI: https://doi.org/10.1360/n972014-00884

2014-01-01

Abstract:Outbreaks of Ebola virus disease (EVD) have been occurring in West Africa (Guinea, Liberia, Sierra Leone, and Nigeria) since December 2013. The etiological agent of this disease, a member of the Ebolavirus genus, was first recognized in 1976. Ebolaviruses have a non-segmented, enveloped, negative-sense RNA genome and are members of the Filoviridae family. There are five recognized species within the Ebolavirus genus: Zaire ebolavirus (EBOV), Sudan ebolavirus (SEBOV), Tai Forest ebolavirus (TAFV), Bundibugyo ebolavirus (BDBV), and Reston ebolavirus (RESTV). The genomes of these viruses contain trailer sequences at the 3 and 5 ends, and genes encoding the following proteins (from the 3 to the 5 end): NP, VP35, VP40, GP, VP30, VP24, and L. Ebolaviruses are classified as category A pathogens, and should be operated under biosafety level four laboratory conditions. The target cells of Ebolaviruses are hepatocytes, endothelial cells, macrophages, and dendritic cells. By depressing innate and adaptive immune responses and increasing vascular permeability, the viruses cause lesions on the liver and other organs. Symptoms of EVD include fever, hemorrhaging, dysfunction, and septic shock. There are currently no licensed antiviral drugs or vaccines against EVD. Therapies under development, or that have been studied in phase I clinical trials, include: the anti-influenza drug T-705, which possibly prevents virus replication in cells; ZMapp, an optimized “cocktail” therapy that includes three humanized antibodies; TKM-Ebola, an RNA interference-based gene therapy; and modulators of coagulation and inflammation. Vaccines under development include replication-deficient vaccines with good safety but long induction times, and live attenuated vaccines with good efficacy but some safety concerns. Further investigation into virology, immunopathology, and pathogenesis of Ebolaviruses will benefit drug and vaccine research and development. At the same time, promising therapies and vaccines should be fast-tracked to human clinical trials.